A double-blind, placebo-controlled, randomized, multicenter study to investigate the safety and efficacy of 2 mg TID of cilansetron over 12 weeks followed by a 4-week rerandomization treatment period in diarrhea predominate irritable bowel syndrome subjects
Latest Information Update: 13 Nov 2006
At a glance
- Drugs Cilansetron (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Solvay Pharmaceuticals
- 13 Nov 2006 New trial record.